Skip to main content

Table 5 Multivariate analysis of ICU mortality for all AG considering targeted Cmax (maximal concentration) attainment

From: An international survey on aminoglycoside practices in critically ill patients: the AMINO III study

  ICU mortality
  OR (95% CI) P value
Medical admission 1.28 [0.75; 2.17] 0.36
Male 1.08 [0.73; 1.60] 0.69
Age (years) 1.03 [1.01; 1.04] 0.001
BMI (kg m−2) 1.00 [0.97; 1.04] 0.8
SOFA score 1.18 [1.10; 1.26]  < 0.0001
Serum creatinine (µmoL L−1) 0.99 [0.99; 1.01] 0.32
Empirical treatment 0.81 [0.45; 1.48] 0.5
Bacteremia 0.62 [0.31; 1.25] 0.18
Cmax attainment 0.78 [0.46; 1.31] 0.34
  1. Italic values indicates P values <0.05
  2. OR were calculated with a GEE model assuming an exchangeable correlation structure. P values result of a Wald test. The regression was based on 393 patients. The targeted Cmax was defined as a serum level above 60 mg L−1 for amikacin and 20 mg L−1 for gentamicin and tobramycin
  3. OR: odds ratio, CI: confidence interval, BMI: body mass index, GEE: generalized estimating equations
\